Abstract
Chemotherapy-Induced Peripheral Neurotoxicity (CIPN) is a side effect frequently caused by common antitumor drugs, which may induce a severe and persistent limitation of the quality of life of cancer patients. Today, nerve conduction studies are considered the most objective indicators for CIPN diagnosis. Unfortunately, they are not easily available at most oncology centers. Therefore, a noninvasive and highly sensitive method is required to confirm nerve damage.
Increased evidence supports the potential utility of fluid-based biomarkers to predict tissue damage and to monitor neurotoxicity due to drug administration or the efficacy of disease-modifying treatments. Neurofilaments, the major intermediate filaments in neurons that are specifically expressed in axons, have been investigated as potential biomarker candidates that might be used for this purpose. Neurofilament light chain (NfL) protein is increasingly proposed as a blood biomarker in several neurological diseases mainly affecting the central nervous system. In addition, analysis of serum NfL was evaluated also in peripheral neuropathies including Guillain–Barré syndrome, chronic inflammatory demyelinating and vasculitic neuropathies, and Charcot–Marie–Tooth.
This chapter aims to provide an overview of the methods that allow NfL quantification in serum, focusing on the most recent ultrasensitive single molecule array (Simoa) assay. This technique is likely to be the best method for NfL dosage in CIPN models to predict the onset of large caliber neuronal dysfunction. Since blood sampling is an easily accessible technique, serum NfL may provide important help to monitor neuroaxonal damage after chemotherapy treatment, and might represent promising tools to follow CIPN progress.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Perrot R, Berges R, Bocquet A et al (2008) Review of the multiple aspects of neurofilament functions, and their possible contribution to neurodegeneration. Mol Neurobiol 38(1):27–65
Perrot R, Eyer J (2009) Neuronal intermediate filaments and neurodegenerative disorders. Brain Res Bull 80(4–5):282–295
Novakova L, Zetterberg H, Sundström P et al (2017) Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology 89(22):2230–2237
Khalil M, Teunissen CE, Otto M et al (2018) Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14(10):577–589
Sandelius Å, Zetterberg H, Blennow K et al (2018) Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology 90(6):e518–e524
Kapoor M, Foiani M, Heslegrave A et al (2019) Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis. J Peripher Nerv Syst 24(4):314–319
Mariotto S, Farinazzo A, Magliozzi R et al (2018) Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies. J Peripher Nerv Syst 23(3):174–177
Bischof A, Manigold T, Barro C et al (2018) Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy. Ann Rheum Dis 77(7):1093–1094
Park SB, Goldstein D, Krishnan AV et al (2013) Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 63(6):419–437
Wolf S, Barton D, Kottschade L et al (2008) Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 44(11):1507–1515
Carozzi VA, Canta A, Chiorazzi A (2015) Chemotherapy-induced peripheral neuropathy: what do we know about mechanisms? Neurosci Lett 596:90–107
Cavaletti G, Marmiroli P (2015) Chemotherapy-induced peripheral neurotoxicity. Curr Opin Neurol 28(5):500–507
Cavaletti G, Frigeni B, Lanzani F et al (2010) Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 46(3):479–494
Cornblath DR, Chaudhry V, Carter K et al (1999) Total neuropathy score: validation and reliability study. Neurology 53(8):1660–1664
Themistocleous AC, Ramirez JD, Serra J et al (2014) The clinical approach to small fibre neuropathy and painful channelopathy. Pract Neurol 14:368–379
Svilpauskaite J, Truffert A, Vaiciene N et al (2006) Electrophysiology of small peripheral nerve fibers in man. A study using the cutaneous silent period. Medicina (Kaunas) 42(4):300–313
Meregalli C, Fumagalli G, Alberti P et al (2018) Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy. Exp Neurol 307:129–132
Meregalli C, Fumagalli G, Alberti P et al (2020) Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of chemotherapy-induced peripheral neurotoxicity. Arch Toxicol. https://doi.org/10.1007/s00204-020-02755-w
Petzold A (2005) Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 233(1–2):183–198
Norgren N, Rosengren L, Stigbrand T (2003) Elevated neurofilament levels in neurological diseases. Brain Res 987(1):25–31
Kuhle J, Nourbakhsh B, Grant D et al (2017) Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology 88(9):826–831
Rissin DM, Kan CW, Campbell TG et al (2010) Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 28(6):595–599
Gisslén M, Price RW, Andreasson U et al (2015) Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine 3:135–140
Rohrer JD, Woollacott IO, Dick KM et al (2016) Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology 87(13):1329–1336
Kuhle J, Barro C, Andreasson U et al (2016) Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med 54(10):1655–1661
Acknowledgments
GC is supported by the Italian PRIN grant (#2017ZFJCS3) and CM is supported by Fondazione Cariplo grant (#2019-1482) . HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931) and the UK Dementia Research Institute at UCL.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Ethics declarations
HZ has served at scientific advisory boards for Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. The other authors declare that they have no conflict of interest.
Rights and permissions
Copyright information
© 2021 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Fumagalli, G., Cavaletti, G., Zetterberg, H., Meregalli, C. (2021). Assessment of Neurofilament Light Protein as a Serum Biomarker in Rodent Models of Toxic-Induced Peripheral Neuropathy. In: Llorens, J., Barenys, M. (eds) Experimental Neurotoxicology Methods. Neuromethods, vol 172. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1637-6_12
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1637-6_12
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1636-9
Online ISBN: 978-1-0716-1637-6
eBook Packages: Springer Protocols